Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Core Viewpoint - Precision BioSciences is conducting an investor update focused on its PBGENE-DMD program, which targets Duchenne Muscular Dystrophy (DMD) [2]. Group 1: Company Overview - Naresh Tanna serves as the Chief of Staff and Head of Investor Relations at Precision BioSciences, leading the investor update [2]. - The management team includes Alex Kelly, Chief Financial Officer, and Dr. Cassie Gorsuch, Chief Scientific Officer, indicating a strong leadership presence [2]. Group 2: Key Participants - The update features contributions from notable figures in the DMD community, including Pat Furlong, Founder of Parent Project Muscular Dystrophy (PPMD), highlighting the company's engagement with advocacy organizations [2]. - Dr. Veerapandiyan, a leading DMD investigator and pediatric neurologist from Arkansas Children's Hospital, is also participating, emphasizing the collaboration with medical experts [3]. Group 3: Forward-Looking Statements - The company has indicated that remarks during the update may contain forward-looking statements based on current expectations, with a caution that actual results could differ materially [3].